Literature DB >> 16107715

Dual functions of the steroid hormone receptor coactivator 3 in modulating resistance to thyroid hormone.

Hao Ying1, Fumihiko Furuya, Mark C Willingham, Jianming Xu, Bert W O'Malley, Sheue-Yann Cheng.   

Abstract

Mutations of the thyroid hormone receptor beta (TRbeta) gene cause resistance to thyroid hormone (RTH). RTH is characterized by increased serum thyroid hormone associated with nonsuppressible thyroid-stimulating hormone (TSH) and impaired growth. It is unclear how the actions of TRbeta mutants are modulated in vivo to affect the manifestation of RTH. Using a mouse model of RTH that harbors a knockin mutation of the TRbeta gene (TRbetaPV mouse), we investigated the effect of the steroid hormone receptor coactivator 3 (SRC-3) on RTH. In TRbetaPV mice deficient in SRC-3, dysfunction of the pituitary-thyroid axis and hypercholesterolemia was lessened, but growth impairment of RTH was worsened. The lessened dysfunction of the pituitary-thyroid axis was attributed to a significant decrease in growth of the thyroid and pituitary. Serum insulin-like growth factor 1 (IGF-1) was further reduced in TRbetaPV mice deficient in SRC-3. This effect led to reduced signaling of the IGF-1/phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway that is known to mediate cell growth and proliferation. Thus, SRC-3 modulates RTH by at least two mechanisms, one via its role as a receptor coregulator and the other via its growth regulatory role through the IGF-1/PI3K/AKT/mTOR signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107715      PMCID: PMC1190271          DOI: 10.1128/MCB.25.17.7687-7695.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  26 in total

Review 1.  Resistance to thyroid hormone.

Authors:  R E Weiss; S Refetoff
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

Review 2.  Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors.

Authors:  S Y Cheng
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

3.  Marked potentiation of the dominant negative action of a mutant thyroid hormone receptor beta in mice by the ablation of one wild-type beta allele.

Authors:  H Suzuki; X-Y Zhang; D Forrest; M C Willingham; S-Y Cheng
Journal:  Mol Endocrinol       Date:  2003-02-06

Review 4.  Molecular basis of resistance to thyroid hormone.

Authors:  Paul M Yen
Journal:  Trends Endocrinol Metab       Date:  2003-09       Impact factor: 12.015

5.  Insulin regulation of insulin-like growth factor-binding protein-1 gene expression is dependent on the mammalian target of rapamycin, but independent of ribosomal S6 kinase activity.

Authors:  Satish Patel; Pamela A Lochhead; Graham Rena; Stefano Fumagalli; Mario Pende; Sara C Kozma; George Thomas; Calum Sutherland
Journal:  J Biol Chem       Date:  2002-01-09       Impact factor: 5.157

6.  Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone.

Authors:  M Kaneshige; K Kaneshige; X Zhu; A Dace; L Garrett; T A Carter; R Kazlauskaite; D G Pankratz; A Wynshaw-Boris; S Refetoff; B Weintraub; M C Willingham; C Barlow; S Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

7.  Regulation of somatic growth by the p160 coactivator p/CIP.

Authors:  Z Wang; D W Rose; O Hermanson; F Liu; T Herman; W Wu; D Szeto; A Gleiberman; A Krones; K Pratt; R Rosenfeld; C K Glass; M G Rosenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

8.  Modulation by steroid receptor coactivator-1 of target-tissue responsiveness in resistance to thyroid hormone.

Authors:  Yuji Kamiya; Xiao-Yong Zhang; Hao Ying; Yusuhito Kato; Mark C Willingham; Jianming Xu; Bert W O'Malley; Sheue-Yann Cheng
Journal:  Endocrinology       Date:  2003-09       Impact factor: 4.736

9.  Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma.

Authors:  Hao Ying; Hideyo Suzuki; Hiroko Furumoto; Robert Walker; Paul Meltzer; Mark C Willingham; Sheue-Yann Cheng
Journal:  Carcinogenesis       Date:  2003-07-17       Impact factor: 4.944

10.  Compensatory role of thyroid hormone receptor (TR) alpha 1 in resistance to thyroid hormone: study in mice with a targeted mutation in the TR beta gene and deficient in TR alpha 1.

Authors:  Hideyo Suzuki; Sheue-Yann Cheng
Journal:  Mol Endocrinol       Date:  2003-05-15
View more
  11 in total

1.  Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.

Authors:  Rebecca E Nakles; Maddalena Tilli Shiffert; Edgar S Díaz-Cruz; M Carla Cabrera; Maram Alotaiby; Anne M Miermont; Anna T Riegel; Priscilla A Furth
Journal:  Mol Endocrinol       Date:  2011-02-03

2.  Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.

Authors:  Fumihiko Furuya; John A Hanover; Sheue-yann Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-30       Impact factor: 11.205

3.  Involvement of SRC-3 in deguelin-induced apoptosis in Jurkat cells.

Authors:  Rui Li; Yan Chen; Wen-xiu Shu; Zi Chen; Wen-juan Ke
Journal:  Int J Hematol       Date:  2009-04-14       Impact factor: 2.490

4.  Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling.

Authors:  Fumihiko Furuya; Celine J Guigon; Li Zhao; Changxue Lu; John A Hanover; Sheue-yann Cheng
Journal:  Mol Cell Biol       Date:  2007-07-02       Impact factor: 4.272

Review 5.  SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.

Authors:  Licen Li; Chu-Xia Deng; Qiang Chen
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

6.  The nuclear cofactor RAC3/AIB1/SRC-3 enhances Nrf2 signaling by interacting with transactivation domains.

Authors:  J-H Kim; S Yu; J D Chen; A N Kong
Journal:  Oncogene       Date:  2012-02-27       Impact factor: 9.867

7.  AIB1 predicts bladder cancer outcome and promotes bladder cancer cell proliferation through AKT and E2F1.

Authors:  Z-T Tong; J-H Wei; J-X Zhang; C-Z Liang; B Liao; J Lu; S Fan; Z-H Chen; F Zhang; H-H Ma; W-C Qian; L-L Kong; Y Fang; W Chen; D Xie; J-H Luo
Journal:  Br J Cancer       Date:  2013-03-19       Impact factor: 7.640

Review 8.  Steroid receptor coactivator 2 is required for female fertility and mammary morphogenesis: insights from the mouse, relevance to the human.

Authors:  Atish Mukherjee; Paula Amato; D Craig Allred; Francesco J DeMayo; John P Lydon
Journal:  Nucl Recept Signal       Date:  2007-11-30

9.  Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor.

Authors:  Fei Yan; Yang Yu; Dar-Chone Chow; Timothy Palzkill; Franck Madoux; Peter Hodder; Peter Chase; Patrick R Griffin; Bert W O'Malley; David M Lonard
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

10.  VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis.

Authors:  Jeon Yeob Jang; Sung Yong Choi; Intae Park; Do Young Park; Kibaek Choe; Pilhan Kim; Young Keum Kim; Byung-Joo Lee; Masanori Hirashima; Yoshiaki Kubota; Jeong-Won Park; Sheue-Yann Cheng; Andras Nagy; Young Joo Park; Kari Alitalo; Minho Shong; Gou Young Koh
Journal:  EMBO Mol Med       Date:  2017-06       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.